ライフサイエンスコーパス: body surface area

1 n 63 patients with major burns (>/=15% total body surface area).

2 emales before but not after normalization to body surface area.

3 iligo involves an estimation of the affected body surface area.

4 y inverted after indexation of RV volumes to body surface area.

5 gnosed AD involving at least 5% of the total body surface area.

6 jected to a full-thickness burn of 30% total body surface area.

7 enting with marked systemic features and low body surface area.

8 dmitted with burns covering 52% of his total body surface area.

9 ere calculated for each variable adjusted to body surface area.

10 pression, particularly in those with smaller body surface area.

11 l vitiligo that involved 15% to 50% of total body surface area.

12 gen, panel reactive antibody >10%, and lower body surface area.

13 5) in end-systolic volume indexed (ESVi) to body surface area.

14 Volumetric measurements were indexed for body surface area.

15 her the hemodynamic measures were indexed to body surface area.

16 njection of 740 MBq (20 mCi) per 1.7 m(2) of body surface area.

17 oving to 73% after accounting for individual body surface area.

18 n the basis of correlation existing with the body surface area.

19 id not correlate with age when normalized to body surface area.

20 on was positively correlated with weight and body surface area.

21 10-point scale), and AD on 10% or greater of body surface area.

22 ARVC patients, particularly when indexed to body surface area.

23 e also reduced with increasing body mass and body surface area.

24 g for clinical covariates, including age and body surface area.

25 associated with older current age and higher body surface area.

26 evaluated with cardiac MRI and normalized to body surface area.

27 rsal scald burn injury covering 30% of total body surface area.

28 t of weight per moisturizer used for a given body surface area.

29 ociated with weight (0.02 mm/kg; P=0.01) and body surface area (1.1 mm/m(2); P<0.001).

30 1 +/- 5.10 g [p = 0.012]) and LVM indexed to body surface area (-1.32 +/- 2.84 g/m(2) vs. placebo gro

31 of LAV is currently performed by indexing to body surface area(1) (BSA(1)).

32 Magna/Magna Ease valves were smaller (median body surface area, 1.42 versus 1.93 m(2); P=0.002) and y

33 olume (left ventricular end-diastolic volume/body surface area, 104+/-13 and 69+/-18 mL/m(2); P<0.001

34 .001; right ventricular end-diastolic volume/body surface area, 110+/-22 and 66+/-16 mL/m(2); P<0.001

35 7 burn patients (mean age, 26.9 years; total body surface area, 16.1%) received 415 laser sessions (2

36 llitus (1.45 [1.39-1.51]), obesity in women (body surface area 2.2 versus 1.8: 1.44 [1.35-1.53]), fem

37 ence in age (65+/-10 versus 59+/-13; P=0.5), body surface area (2.0+/-0.2 versus 2.0+/-0.2 m(2); P=0.

38 with 2 infusions of rituximab, 500 mg/m2 of body surface area, 2 weeks apart, followed by 4 maintena

39 (SD) athlete height was 200.2 (8.8) cm; mean body surface area, 2.38 (0.19) m2.

40 Patients with lower burn severity (total body surface area, 20-30%) express similar metabolic alt

41 than those with hypertension (LA volume max/ body surface area 30.2+/-6.6 versus 33.0+/-9.0 mL/m(2);

42 /-10 g/m(2); P<0.001; right ventricular mass/body surface area, 36+/-7 and 24+/-5 g/m(2); P<0.001) an

43 of sunscreen per 1 cm2 was applied to 75% of body surface area 4 times per day for 4 days, and 30 blo

44 29%]) or based on body weight (10 [48%]) and body surface area (4 [19%]).

45 4 [16.9] mL/min/1.73m(2), LV mass indexed to body surface area 60.7 [11.9] g/m(2)), 90 had evaluable

46 edian age 40 years, median burn size 6.0% of body surface area), 71% were men and 76% were White.

47 ight ventricular mass (left ventricular mass/body surface area, 96+/-13 and 62+/-10 g/m(2); P<0.001;

48 easurements were corrected for age, sex, and body surface area according to reference data and progno

49 ered intravenously) or cisplatin (70 mg/m(2) body surface area administered intravenously) on day 1 o

50 rapy at a dose of 375 mg per square meter of body-surface area administered every 2 months for 3 year

51 mpared rituximab (375 mg per square meter of body-surface area administered once a week for 4 weeks)

52 d 21-day cycles of gemcitabine (1000 mg/m(2) body surface area, administered intravenously on days 1

53 erity Index [EASI] score >=16, percentage of body surface area affected >=10%, and Peak Pruritus Nume

54 reased in a stepwise fashion with increasing body surface area affected by PsO (P for trend <0.001).

55 8-32 years]) were all male with an estimated body surface area affected with RDEB of 4% to 30%.

56 evere psoriasis defined by 3% or more of the body surface area affected.

57 evere disease) and with 10% or more of their body-surface area affected by psoriasis to receive broda

58 significant reduction in LV mass indexed to body surface area after 6 months, which may account in p

59 3 x 10(6) CAR-NKT cells per square meter of body surface area after lymphodepleting conditioning wit

60 ace area before vs. 58.9 +/- 17.5 mL/min per body surface area after therapy; P = 0.22); however, 3 p

61 Total body surface area, age, and inhalation injury had signif

62 apy using verteporfin at a dose of 6 mg/m(2) body surface area and 689 nm diode laser at an intensity

63 lied with verteporfin at a dose of 6 mg/m(2) body surface area and a 689 nm diode laser for 83 second

64 Great vessel areas correlated well with body surface area and age in controls and reference Z-sc

65 unilateral pectoralis muscle mass indexed to body surface area and attenuation (approximated by mean

66 cases, such as severe burns on >30% of total body surface area and EB.

67 mited disease to involvement of 30% of their body surface area and had evidence of pulmonary sarcoido

68 ion of the myocardium, indexed ECV (iECV) to body surface area and late gadolinium enhancement.

69 6 weeks in LV end-systolic volume indexed to body surface area and LV global longitudinal strain both

70 th burns covering more than 20% of the total body surface area and required at least one surgical int

71 es in end-diastolic volume indexed (EDVi) to body surface area and the ejection fraction (EF).

72 eters corresponding to pesticide deposition, body surface area and weight, surface-to-body transfer e

73 of 30 to <90 ml per minute per 1.73 m(2) of body-surface area and albuminuria (ratio of albumin [mg]

74 f at least 40 ml per minute per 1.73 m(2) of body-surface area and had been receiving angiotensin-sys

75 30.0 to 89.9 ml per minute per 1.73 m(2) of body-surface area and then randomly assigned them to rec

76 males (27.8 +/- 2.7 years; 1.92 +/- 0.1 m(2) body surface area) and 10 females (25.4 +/- 3.9 years; 1

77 erapy (melphalan, 140 mg per square meter of body-surface area) and autologous stem-cell transplantat

78 ive gemcitabine (1000 mg per square meter of body-surface area) and carboplatin (at a dose equivalent

79 apy with intravenous fludarabine (30 mg/m(2) body-surface area) and cyclophosphamide (500 mg/m(2) bod

80 ceive bortezomib (1.3 mg per square meter of body-surface area) and dexamethasone (20 mg) alone (cont

81 ate, 25 to 60 ml per minute per 1.73 m(2) of body-surface area), and risks for cardiovascular disease

82 ndence after TP-IAT: (1) male sex, (2) lower body surface area, and (3) higher total IEQ per kilogram

83 on rate (eGFR) 25-75 mL/min per 1.73 m(2) of body surface area, and a urine albumin-to-creatinine rat

84 hysiology and Chronic Health Evaluation III, body surface area, and age, sarcopenia index was indepen

85 re independent of age when dose is scaled to body surface area, and ESA resistance is associated with

86 sociations of age, body length, body weight, body surface area, and heart rate on PAAT were investiga

87 Age, sex, body surface area, and high-level endurance training wer

88 sions, parameters of body size (body weight, body surface area, and organ circumference) and gestatio

89 mass and function after controlling for age, body surface area, and sex.

90 malizing to body weight, lean body mass, and body surface area, and simplified measurements were comp

91 starting dose of everolimus depended on age, body-surface area, and concomitant use of cytochrome 3A4

92 less than 60 ml per minute per 1.73 m(2) of body-surface area, and diabetic retinopathy, or they had

93 40.0 to 99.9 ml per minute per 1.73 m(2) of body-surface area, and evidence of diabetic kidney disea

94 -weekly cycles of paclitaxel [175 mg/m(2) of body surface area] and carboplatin [area under the curve

95 ns, necessary program experience, donor with body surface area appropriate for recipient, and improve

96 en product was applied at 2 mg/cm2 to 75% of body surface area at 0 hours on day 1 and 4 times on day

97 , days in intensive care unit, sex, age, and body surface area at evaluation.

98 in the Psoriasis Area and Severity Index and body surface area at the end of treatment.

99 ity alleles presented a greater reduction in body surface area at the intermediate point, which remai

100 sed LV end-diastolic volume [EDV] indexed to body surface area) at baseline were excluded.

101 males (25.4 +/- 3.9 years; 1.68 +/- 0.1 m(2) body surface area), at rest and post maximal incremental

102 atients with aortic valve area normalized to body surface area (AVA/BSA) <0.6 cm(2)/m(2); yet, this c

103 On the basis of AVA-indexed-to-body surface area (AVAi) and MG, patients were categoriz

104 e or after therapy (64.2 +/- 16.5 mL/min per body surface area before vs. 58.9 +/- 17.5 mL/min per bo

105 0 [95% CI, 2.2-22.8]; p < 0.001), a detached body surface area between 10% and 29% (odds ratio, 3.7 [

106 s in absolute and adjusted GS (corrected for body surface area) between 1 and 12 months after transpl

107 pigmentation of 0.5% or more of their facial body surface area (BSA) and 3% or more of their non-faci

108 effective diameters at each level to patient body surface area (BSA) and sex.

109 scores for common measurements adjusted for body surface area (BSA) and stratified by age, sex, race

110 ss index (BMI; weight (kg)/height (m)2), and body surface area (BSA) at ages 7-13 years and birth wei

111 values for FAC, TAPSE, and TAPSE indexed to body surface area (BSA) decreased over time (P=0.03 for

112 Recorded variables included maximal body surface area (BSA) detachment, SCORTEN (Score of To

113 l dose of 2.2 x 10(11) platelets/transfusion/body surface area (BSA) do not affect any bleeding grade

114 Body surface area (BSA) of vitiligo lesions.RESULTS Pati

115 According to donor/recipient body surface area (BSA) ratio, patients were stratified

116 Body surface area (BSA) scaling has been used for prescr

117 xtensive cutaneous disease involving >90% of body surface area (BSA) suffered from severe symptoms re

118 End-systolic volume and end-diastolic volume/body surface area (BSA) were 62 (45-101) and 104 (83-143

119 nalysis, log-creatinine, sex, age, race, and body surface area (BSA) were significantly associated wi

120 xceptionally severe psoriasis at entry (>42% body surface area (BSA)) had a significantly increased r

121 2,044 participants had mild psoriasis (</=2% body surface area (BSA)), 1,377 had moderate psoriasis (

122 ncer was higher for participants with a high body surface area (BSA), great height, or excess weight

123 Body surface area (BSA)-adjusted chronic kidney disease

124 sage of the radiopharmaceutical according to body surface area (BSA).

125 , weight, height, body mass index (BMI), and body surface area (BSA).

126 stage II (end-diastolic volume [milliliters]/body surface area [BSA](1.3), end-systolic volume [milli

127 -diastolic volume (LVDV) was 40 mL (LVDV per body surface area [BSA], 25 mL/m(2)); left ventricular e

128 aluated whether the effect of clinical (age, body surface area [BSA], chronic kidney disease [CKD], a

129 e also identified between clinical measures (body surface area/BSA, pruritus ADQ, and transepidermal

130 ax laboratories and subjected to a 30% total body surface area burn injury.

131 andard deviation 17) years with median total body surface area burn of 15% [interquartile range (IQR)

132 hours after injury, and more than 20% total body surface area burn requiring at least 1 surgical int

133 12 male pediatric burn patients (>30% total body surface area burn) and 12 young, healthy male subje

134 ed the varying effects of patient age, total body surface area burn, and inhalation injury on the pro

135 owed that a burn size of more than 60% total body surface area burned (an increase from 40% a decade

136 urn care setting, adults with over 40% total body surface area burned and children with over 60% tota

137 area burned and children with over 60% total body surface area burned are at high risk for morbidity

138 of 612 burned children [52% +/- 1% of total body surface area burned, ages 0.5-14 years (boys); ages

139 ome after controlling for age, gender, total body surface area burned, and inhalation injury (hazard

140 Age, total body surface area burned, and inhalation injury were als

141 +/- 15 years old and with 38% +/- 14% total body surface area burned, underwent an oral glucose tole

142 tcomes was lower, at approximately 40% total body surface area burned.

143 le organ failure was approximately 60% total body surface area burned.

144 er than 18 years or with more than 20% total body surface area burns (TBSA) burns were excluded.

145 nts (>/=16 years old) with 20% or more total body surface area burns recruited from 6 US burn centers

146 hours after injury, and more than 20% total body surface area burns requiring at least one surgical

147 pediatric patients with more than 30% total body surface area burns were randomized to control (n =

148 escribe a 22-year-old soldier with 19% total body surface area burns, polytrauma, and sequence- and c

149 was admitted to the burn unit with 50% total body surface area burns.

150 tients, including 1476 with burns >20% total body surface area, by presence of AKI.

151 Cardiac output was indexed to body surface area (cardiac index [CI]) for all analyses.

152 zation, and echocardiography) and indexed to body surface area (cardiac index [CI]).

153 r were divided into two cohorts according to body-surface area (cohort 1, <0.7 m(2); cohort 2, 0.7 to

154 full-thickness thermal injury (30% of total body surface area), cold stress (4 degrees C for 24 h),

155 d mild, moderate, or severe disease based on body surface area criteria.

156 n Renal Disease formula result multiplied by body surface area divided by 1.73 m(2)) and the presence

157 ce (n=121) of methotrexate (40-60 mg/m(2) of body surface area), docetaxel (30-40 mg/m(2)), or cetuxi

158 d-diastolic and -systolic volumes indexed to body surface area, ejection fraction, 24-hour ambulatory

159 rogen deprivation plus docetaxel (75 mg/m(2) body surface area every 3 weeks for 6 cycles) and RP.

160 ose of 0.75 (adjusted to 0.5 to 1.0) g/m2 of body surface area every 4 weeks for 6 months.

161 ne (at a dose of 1000 mg per square meter of body-surface area every 3 weeks and nivolumab-matched pl

162 axel (at a dose of 75 mg per square meter of body-surface area every 3 weeks for six cycles) or ADT a

163 usly at a dose of 175 mg per square meter of body-surface area every 3 weeks, plus carboplatin (dose

164 axel, at a dose of 75 mg per square meter of body-surface area every 3 weeks.

165 taxel at a dose of 75 mg per square meter of body-surface area every 3 weeks.

166 o nab-paclitaxel (125 mg per square meter of body-surface area) followed by gemcitabine (1000 mg per

167 e) and paclitaxel (50 mg per square meter of body-surface area) for 5 weeks and concurrent radiothera

168 was the 6-month change in LV mass indexed to body surface area from baseline as measured by cardiac m

169 [eGFR] of <5 ml per minute per 1.73 m(2) of body-surface area from baseline) and a decrease in the e

170 efore receiving an approximately 12.5% total body surface area full thickness burn.

171 Patients with LVH (LVM/body surface area >/=116 and >/=96 g/m(2) in men and wom

172 hysician's Global Assessment score >/=3 with body surface area >10%).

173 rations as patients with larger burns (total body surface area, >/= 30%).

174 atients with moderate-to-severe AD (affected body surface area, >=10%; Eczema Area and Severity Index

175 imum aortic-root-diameter z score indexed to body-surface area (hereafter, aortic-root z score) over

176 l ventilation had a larger baseline detached body surface area, higher Logistic Organ Dysfunction sco

177 based on CAC-CT radiomics, sex, height, and body surface area in a random training subset of 1587 pa

178 o monitor accurately and easily the affected body surface area in a standardized way.

179 ty as objectively determined by the affected body surface area in both unadjusted and adjusted analys

180 rdial infarction (1.24 [1.08-1.42]), and low body surface area in men (1.22 [1.14-1.30]).

181 VESVI was 41.2+/-20.0 ml per square meter of body-surface area in the CABG-alone group and 43.2+/-20.

182 ients was 46.1+/-22.4 ml per square meter of body-surface area in the CABG-alone group and 49.6+/-31.

183 ere 68 and 70 ml per minute per 1.73 m(2) of body-surface area in the development and validation data

184 at least 3.0 ml per minute per 1.73 m(2) of body-surface area in the preceding year to receive allop

185 ients was 54.6+/-25.0 ml per square meter of body-surface area in the repair group and 60.7+/-31.5 ml

186 and efficacy of 32 doses of BTZ (1.3 mg/m of body surface area) in 10 highly sensitized kidney transp

187 ] of 20 to 45 ml per minute per 1.73 m(2) of body-surface area) in a 1:1:1:1 ratio to receive placebo

188 ant trend, independent of age, toward larger body surface area-indexed ascending aortic diameters wit

189 and (3) the echocardiographically measured, body surface area-indexed, effective orifice area (EOAi

190 twice daily) or dacarbazine (1000 mg/m(2) of body surface area intravenously every 3 weeks).

191 -day cycle and nab-paclitaxel 100 mg/m(2) of body surface area intravenously on days 1, 8, and 15 unt

192 or dacarbazine (1000 mg per square meter of body-surface area intravenously every 3 weeks).

193 axel (at a dose of 25 mg per square meter of body-surface area intravenously every 3 weeks, plus pred

194 moderate-to-severe chronic plaque psoriasis (body surface area involvement >/=10%, Physician's Global

195 ab, P = .005; and AHA, P = .006), extensive body surface area involvement (ssDNA ab, P = .01; and AN

196 Greater body surface area involvement was associated with poorer

197 ic records of patients with either SJS (<30% body surface area involvement) or TEN (> = 30% involveme

198 ore baseline (randomisation), 10% or greater body-surface area involvement at both screening and base

199 hysician's Global Assessment score </=3 with body surface area </=10%) or severe (worst Physician's G

200 ea <=1 cm(2) or aortic valve area indexed to body surface area <=0.6 cm(2)/m(2) and mean aortic press

201 or primary outcomes: LV end-diastolic volume/body surface area, LV ejection fraction, LV end-diastoli

202 adius/wall thickness; LV end-systolic volume/body surface area, LV longitudinal strain rate, and LV e

203 LVM indexed to body surface area (LVMI) and MWT were significantly high

204 ved intravenous infusion of IdU (200 mg/m(2) body surface area; maximum dose, 400 mg) over a 30-minut

205 and 1242 women) aged 23.1+/-5.7 years, with body surface area of 1.9+/-0.2 m(2) and 8.9+/-4.9 years

206 57.1 and 53.6 years, respectively, P<0.0001; body surface area of 2.4 and 2.1 m(2), respectively, P<0

207 Fifty-four patients with burns to total body surface area of greater than or equal to 15%, intub

208 s of subcutaneous bortezomib (1.3 mg/m(2) of body surface area on days 1, 4, 8, 11, 22, 25, 29, and 3

209 des and the LV mass index (LVMI) (indexed to body surface area on echocardiography, 67 patients).

210 daily at a dose of 25 mg per square meter of body-surface area on a continuous dosing schedule (28-da

211 at a dose of 20 to 30 mg per square meter of body-surface area on a continuous dosing schedule (in 28

212 ing of docetaxel (100 mg per square meter of body-surface area on day 1), docetaxel (75 mg per square

213 omib at a dose of 1.3 mg per square meter of body-surface area on days 1, 4, 8, and 11).

214 ion of etoposide (100 mg per square meter of body-surface area on days 2 to 4), doxorubicin (40 mg pe

215 ) and intravenous paclitaxel (175 mg/m(2) by body surface area) on day 1 of every 21-day cycle (contr

216 dose-fractionated paclitaxel (80 mg/m(2) by body surface area) on days 1, 8, and 15 of every 21-day

217 dose-fractionated paclitaxel (80 mg/m(2) by body surface area) on days 1, 8, and 15 of every 21-day

218 face area) and cyclophosphamide (500 mg/m(2) body-surface area) on days -5, -4, and -3.

219 h cisplatin-based chemoradiation (40 mg/m(2) body surface area once per week with a planned total dos

220 001) even after adjustment for their smaller body surface area or aortic annular area (both P<0.0001)

221 R of 25 to 65 ml per minute per 1.73 m(2) of body-surface area or 56 to 65 years of age with an estim

222 r >/=upper 90th percentile for age, sex, and body surface area) or not enlarged; the hazard of an adv

223 n [AUC 5 or 6] and paclitaxel 175 mg/m(2) of body surface area) or the same chemotherapy regimen plus

224 ving cisplatin (>/=70 mg per square meter of body-surface area) or cyclophosphamide-doxorubicin.

225 ither pemetrexed (500 mg per square meter of body-surface area) or docetaxel (75 mg per square meter)

226 ous dacarbazine (1000 mg per square meter of body-surface area) or paclitaxel (175 mg per square mete

227 0 +/- 6.3 to 75.5 +/- 6.3 mL.min(-1) . m(-2) body surface area (P < 0.01), because of improvements in

228 After adjusting for age (P = .090), body surface area (P = .073), and sex (P = .005), pulmon

229 f prior Puestow procedure (P = 0.018), lower body surface area (P = 0.048), higher islet equivalents

230 39 versus 112+/-33 mL/BSA(1.3), where BSA is body surface area; P=0.02).

231 agnetic resonance measures for age, sex, and body surface area, particularly given the changing demog

232 ated using pectoralis muscle area indexed to body surface area (pectoralis muscle index).

233 tered at a dose of 20 mg per square meter of body-surface area per day for 10 consecutive days in mon

234 of fluorouracil (500 mg per square meter of body-surface area per day) during fractions 1 to 5 and 1

235 alan at a dose of 200 mg per square meter of body-surface area plus autologous stem-cell transplantat

236 axel at a dose of 175 mg per square meter of body-surface area, plus carboplatin at an area under the

237 latin at a dose of 50 mg per square meter of body-surface area, plus paclitaxel at a dose of 135 or 1

238 ed with increasing body mass (r = -0.41) and body surface area (r = -0.37).

239 y with age (r=0.848), body length (r=0.871), body surface area (r=0.856), and body weight (r=0.825) a

240 related with the degree of RVH (RV thickness/body surface area; r(2)=0.838 and r(2)=0.818, respective

241 ricular indexed end-diastolic volume >125 mL/body surface area raised to the 1.3 power was associated

242 ormulas (Lin or Vauthey using body weight or body surface area) rather than Urata's.

243 Donor-to-recipient body surface area ratio <0.90 had a RR of 1.40 (1.13-1.7

244 Mean LV mass indexed to body surface area regression over 6 months was 2.6 g/m(2

245 -1.51+/-1.33 ml per minute per 1.73 m(2) of body-surface area, respectively.

246 ce: Standard dosing of chemotherapy based on body surface area results in marked interpatient variati

247 Corrected for age, sex, and body surface area, right ventricular end-systolic volume

248 Body surface area seems to be appropriate for indexation

249 of stroke between 11 and 365 days were small body surface area, severe aortic calcification, and fall

250 nt confirmed and then subjected to 30% total body surface area steam burn injury.

251 LVEF of >/=50% but stroke volume indexed to body surface area (SVi) of </=35 ml m(-2); and 629 (54%)

252 After adjusting for age, race, body surface area, systolic blood pressure, history of h

253 lly injured, as demonstrated by mean % total body surface area (TBSA) (41.2 +/- 18.3 for adults and 5

254 included in the analysis, with a mean total body surface area (TBSA) burn of 7.2% and a mean age of

255 ll transfusion strategy in 20% or more total body surface area (TBSA) burn patients.

256 ned adult patients with burns over 20% total body surface area (TBSA) burn were prospectively randomi

257 ty, even after adjusting for age and % total body surface area (TBSA) burn.

258 jects is 42.5 +/- 16.0 years, the mean total body surface area (TBSA) burned is 18.5 +/- 16.4%, and t

259 rn survivors aged >=18 years with >=5% total body surface area (TBSA) or burns to critical areas.

260 ts with burns of at least 30% of their total body surface area (TBSA).

261 45 mm, lowered toward 40 in females with low body surface area, TGFBR2 mutation, and severe extra-aor

262 n multivariate regression analyses including body surface area, the 3 different MVA methods, and dPme

263 The animals were exposed to 40% total body surface area third degree skin flame burn and 48 br

264 rn and smoke inhalation injury (40% of total body surface area, third-degree flame burn; 4 x 12 breat

265 18 of these 92 products, a minimum weight or body surface area threshold is recommended for adolescen

266 rn injury greater than or equal to 20% total body surface area to our burn center from 2011 to 2016.

267 meter-derived diameter, which was divided by body surface area to produce an indexed annulus size.

268 f at least 30 ml per minute per 1.73 m(2) of body-surface area to receive either empagliflozin (at a

269 years) with severe burn injury (>= 20% total body surface area) to generate training and test dataset

270 sed cardiac index (cardiac output divided by body surface area) to incident all-cause dementia and Al

271 R], 15 to <30 ml per minute per 1.73 m(2) of body-surface area) to bardoxolone methyl, at a daily dos

272 ate [GFR] >60 ml per minute per 1.73 m(2) of body-surface area) to either a standard blood-pressure t

273 FR], 25 to 60 ml per minute per 1.73 m(2) of body-surface area) to receive an ACE inhibitor (lisinopr

274 Propensity matching based on age, sex, body surface area, total fluoroscopy time, and total acq

275 the eTLV (calculated as -794.41 + 1267.28 x body surface area) using volumetric data (cm) and clinic

276 ed to the same suberythemal UVR dose, to 85% body surface area, using solar simulated UVR or narrowba

277 Renal blood flow indexed to body surface area was 244 mL/min/m2 (range 165-662) in s

278 The total body surface area was 33% (22%-52%).

279 METHODS AND LA volume indexed to body surface area was measured by cardiovascular magneti

280 h age, height, and weight, normalization for body surface area was most efficient in removing the eff

281 less than 60 ml per minute per 1.73 m(2) of body-surface area was higher with the cystatin C-based e

282 terquartile range) age, body mass index, and body surface area were 68 (57-77) years, 28 (24-34) kg/m

283 he Psoriasis Area and Severity Index and the body surface area were assessed at baseline and at treat

284 ney morphological characteristics indexed to body surface area were associated inversely and independ

285 perative computed tomographic scans and (ii) body surface area were available entered the study.

286 3 (mild or moderate), and 3% to 20% affected body surface area were equally randomized for 8 weeks of

287 Dimensions corrected by body surface area were higher in men than in women at th

288 mTFC parameters indexed for body surface area were significantly more abnormal in pa

289 3DE LA volumes indexed by body surface area were similar in men and women and incr

290 Age and body surface area were similar in the 4 valve morphology

291 Age, left ventricular mass, and body surface area were the main predictors of aortic dim

292 (mL/kg) and per percentage burn (mL/kg/total body surface area) were also lower for the computer deci

293 ase (eGFR <60 ml per minute per 1.73 m(2) of body-surface area) were analyzed with the use of linear

294 left atrial end-diastolic volume indexed to body surface area, were assessed using cine cardiovascul

295 ne dose of 4.3 g or more per square meter of body-surface area (which has been associated with premat

296 2015 and October 2018 with burns >=15% total body surface area with regard to infection and sepsis (S

297 Cluster 1 had high SASSAD scores and body surface areas with the highest levels of pulmonary

298 ease in the aortic-root diameter relative to body-surface area with either treatment.

299 VESVI was 52.6+/-27.7 ml per square meter of body-surface area with mitral-valve repair and 60.6+/-39

300 e, 9-40 years) and were indexed according to body surface area, with internal validation (R(2) = 0.84